A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed (SOLAR)

Conditions

HIV/AIDS

Phase IIIb

Volunteers
Health Professionals

What is the purpose of this trial?

This study is designed to assess the antiviral activity and safety of a two-drug regimen of CAB LA + RPV LA compared with maintenance of BIK. BIKTARVY is a registered trademark of Gilead Sciences.

Ages
18 years and older
Gender
Both

Find out more about who can participate in this trial

Trial with
ViiV Healthcare Company
Start Date
04/07/2021
End Date
07/05/2022

For more information about this study, contact:

Laurie Andrews

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Onyema Ogbuagu, MBBCh, FACP, FIDSA
Associate Professor of Medicine (AIDS); Affiliated Faculty, Yale Institute for Global Health

Sub-Investigators

Last Updated
05/09/2022
Study HIC
#2000029306

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed (SOLAR)

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigators

Contact Information